1 : 0/2) and 2 control girls (hyper/hypo: 1/
1)
met the same criteria in only 1 region/person.
2 Results: Of the 2,136 responses, 1,
111 met the inclusion criteria.
3 nt by 5 years after enrollment; of these,
12 met the study endpoint and another 13 had radiologic pro
4 Of 101 included trials,
12 met statistical significance for their main endpoint, fi
5 were selected for a full-text review, and
13 met the inclusion criteria and were assigned a quality-o
6 Of the 316 transfused patients,
136 met a 28-day outcome and were matched to 251 non-transfu
7 atients' records were reviewed, of which
151 met the inclusion criteria.
8 Of 201 patients evaluated,
163 met inclusion criteria: 116 anomalous right CA (71%), 25
9 D4 + T-cell-counts >= 500/ul, among them
178 met the inclusion criteria for the 10-year study.
10 sults Thirty men (81%) and seven women (
19%)
met the inclusion criteria, with a mean age of 61 years
11 ,470 critically injured children, 103 (4.
2%)
met pediatric acute respiratory distress syndrome criter
12 1 individuals screened (11/2016-7/2017),
200 met inclusion criteria; 58% injected drugs and 31% share
13 26 articles published between 1939 and
2008 met inclusion criteria.
14 nrolled between August 2016 and October
2017 met study criteria for confirmed (febrile illness and cu
15 (dual therapy, 993; monotherapy, 1121);
23%
met the primary outcome.
16 oped IM; 6 months later, 55 of the 238 (
23%)
met criteria for ME/CFS and 157 (66%) were asymptomatic.
17 Of 5862 reports identified by the search,
28 met the inclusion criteria: 20 were cross-sectional and
18 Among 2,084 patients, 1,
289 met the inclusion criteria.
19 ne clinical evaluation, and 17 of 51 (33.
3%)
met diagnostic criteria for CPVT.
20 erienced clinically relevant events, and
35%
met the composite outcome (all-cause death [n=128], card
21 ms and identified 1928 articles, of which
37 met our inclusion criteria.
22 Of 215 patients,
38 met the criteria for definite ALPS and 17 for suspected
23 reat analysis, 19 of 22 participants (86.
4%)
met remission criteria.
24 red seventy-two articles were identified;
41 met the inclusion criteria outlined for assessment and w
25 ompleted the final pain assessment, 74 (
41%)
met criteria for chronic postsurgical pain (CPSP), that
26 Of the 80 subjects, 6 (7.
5%)
met the primary and 4 (5%) the secondary endpoint.
27 Nineteen of 21 participants (90.
5%)
met remission criteria (defined as a score <11 on the Mo
28 =18 years old, had a body mass index >=18.
5,
met criteria for DSM-5 binge eating disorder or bulimia
29 r opioids after hospital discharge, and 2.
6%
met criteria for persistent use, an average of 300 new p
30 nsecutive admissions (23 centers), 1494 (
6%)
met criteria for analysis.
31 h all scheduled study visits and 178 (45.
6%)
met criteria for noncompliance, with 53 (13.6%) subjects
32 Of the 227 adult donor livers split,
61%
met United Network for Organ Sharing "optimal" split cri
33 From a total of 882 reviews,
63 met the inclusion criteria, and 900 studies were identif
34 Of these, 1750 (
65%)
met all of the eligibility criteria on telephone screeni
35 patients with acute neurologic symptoms,
73 met the inclusion criteria and were included (23.7%): th
36 A total of 109 individuals (2.
8%)
met criteria for a psychotic disorder up to age 24, of w
37 1 336 female CCSS participants, 5886 (51.
9%)
met all inclusion criteria for analysis.
38 tients were identified, of which 577 (52.
9%)
met PIVOT criteria.
39 Of the 88 carriers,
93%
met criteria for beta-blocker treatment and 5/88 (5.7%)
40 .6%) had asymmetric, bilateral amblyopia;
98 met inclusion and exclusion criteria.
41 Pre-MI, fewer younger
adults met guideline indications for 3-hydroxy-3-methyl-glutary
42 Nineteen cases (11 children, 8
adults)
met criteria for SFR meningoencephalitis.
43 , an estimated 0.6% (95% CI, 0.5%-0.6%)
also met the guideline threshold for antihypertensive therapy
44 rvival as CA TCMR when biopsy specimens
also met Banff criteria for TCMR and/or AMR.
45 based microfluidics for single cell
analysis met problems.
46 A preplanned interim
analysis met the efficacy criterion for early closure after recru
47 e interval, 0.87-2.82; 1-sided P = .068)
and met the prespecified 1-sided alpha of 0.10.
48 atients underwent inguinal hernia repair
and met inclusion criteria.
49 FR scFvs at low concentrations of sEGFR,
and met the clinically required detection range of sEGFR.
50 The modified method was validated
and met the performance criteria required by the EU Regulati
51 71/74 (95.9%) randomized to oral
antibiotics met the primary endpoint compared with 72/78 (92.3%) ran
52 Our mHealth system
appropriately met the requirements of application in patients' homes,
53 If certain assumptions
are met, estimates from MR should be free from most environm
54 When these challenges
are met, machine learning promises a future of rigorous, out
55 Cellular energy demands
are met by uptake and metabolism of nutrients like glucose.
56 When such expectations
are met by a following social stimulus - an upright face - i
57 the micronutrient needs of both parties
are met.
58 A total of 111
articles met our inclusion criteria.
59 3,433 records were identified, 181
articles met selection criteria, and the largest subset of task t
60 6 268 articles were screened and 78
articles met inclusion criteria with outcomes in surface contamin
61 Fifty-eight
articles met eligibility criteria and formed the evidentiary basi
62 Twenty
articles met the inclusion criteria for this assessment and were
63 es for allergic conditions other than
asthma met the inclusion criteria.
64 hepatic multi-scale vascular network can
be met thanks to the constructal law of design evolution.
65 Projected rubber demand could
be met by allowing expansion primarily in New Guinea and Af
66 example, global artemisinin demand could
be met with fewer than 10 biorefineries, while global deman
67 This challenge might
be met through canonical correlation analysis designed to m
68 e global traffic deaths by 2020, will not
be met by most low-income and middle-income countries (LMIC
69 Three criteria should
be met in order to be considered a successful outcome: firs
70 be expressing an unmet need, which should
be met.
71 we propose five criteria that all need to
be met to demonstrate that temperature-mediated trophic asy
72 ind that the following conditions have to
be met to robustly assemble the bipolar spindle in a multic
73 ed oxygen (Fio2) criteria for ARDS had to
be met within a 24-hour period, and the administration of t
74 is a biomedical challenge that has yet to
be met(3-9).
75 nd/or reactor failure, two metrics had to
be met: (a) a methanogenesis to fermentation ratio higher t
76 the likelihood that the EOT target has
been met locally.
77 n moiety, but to date this approach has
been met with little success.
78 ihood that their elimination target has
been met, and where to invest in additional sampling.
79 s and halt species extinctions are not
being met despite decades of conservation action.
80 A total of 4 451 200
beneficiaries met inclusion criteria; 3 805 718 (85.5%) received eye c
81 l10-mediated vicious cycle, cultivating a
br-
met-promoting, immune-suppressive niche.
82 Additionally,
br-
met-associated CNS-myeloid exhibited downregulation of C
83 Brain metastasis (
br-
met) develops in an immunologically unique br-met niche.
84 g relieved immune suppression and reduced
br-
met burden.
85 et) develops in an immunologically unique
br-
met niche.
86 ient had no evidence of cardiac disease,
but met possible ARVC diagnosis with one major criterion (th
87 MCT 74% of patients compared with 52% in
CBT met formal criteria for recovery on the BDI-II at post t
88 Most health
centers met the Healthy People 2020 baseline, but opportunities
89 nts from the FROG-ICU and AdrenOSS-1
cohorts met the definition of sub-AKI (11.6% and 17.5% of patien
90 Six
cohorts met the inclusion criteria, with IPD on 23,038 participa
91 Overall, 70.2% of e-
consults met all 4 criteria for appropriateness; the frequency of
92 oals targets for education and
contraceptive met need would result in a global population of 6.29 bil
93 of educational attainment and
contraceptive met need.
94 One hundred thirty-three
controls met all criteria at an outpatient encounter.
95 treated with standard of care and
dabigatran met the composite efficacy endpoint (38 [42%] of 90 vs 8
96 riple-negative breast cancer in the
database met the inclusion criteria for this analysis.
97 a defining feature distinguishing
different met-types.
98 While 28% of DO
donors met splitting criteria, only 3% of those meeting splitti
99 lder adults (n = 104; aged 60-80) who
either met (n = 31) or did not meet (n = 73) criteria for insom
100 CT, the proportion with ILD events (
endpoint met or radiographic ILA progression) was calculated.Meas
101 ort on phase I and II studies of
entrectinib met the inclusion criteria and inform the guideline upda
102 nternational academic and government
experts met in March 2019 to frame the initial inquiry, which wa
103 Unfortunately, such methods have thus
far met with limited success.
104 59.2% (n = 77) and 22.7% (n = 17) of
fellows met criteria for burnout.
105 Younger patients less
frequently met very high-risk criteria for intensive secondary prev
106 d by the experts, after which the COTS
group met in November 2019 for a systematic and critical discu
107 r group and 129 (84%) in the efavirenz
group met the primary efficacy outcome (absolute difference 10
108 At week 12, the etrasimod 2 mg
group met the primary and all secondary endpoints.
109 ly, the empowering of regulatory subsets
has met success in mitigating autoimmune diseases.
110 Caulobacter crescentus is a species that
has met this need effectively, as its dimorphic lifestyle sh
111 the proportion of patients who benefit
have met with challenges of limited efficacy and/or significa
112 ients (43%) in this SOC study would not
have met ZUMA-1 eligibility criteria because of comorbidities
113 al architectures-as opposed to polymers-
have met with limited success.
114 etter characterize experimental systems
have met challenges due to assumptions necessary by the vario
115 of previous drug of abuse vaccines that
have met limited success in the past.
116 translate this success to solid tumors
have met with limited success.
117 inic discounts offsetting costs
historically met through illegal logging.
118 Both dose strengths of bimatoprost
implant met the primary end point of noninferiority to timolol t
119 Increases over time
in met need for contraception were correlated with increase
120 ater quantity indicators, and
inconsistently met water quality indicators.
121 A total of 37,163
individuals met study inclusion criteria; 10.4% were tested by IGRA.
122 ay mortality; and whether the InfA
infection met criteria for a health care-associated influenza A in
123 rimary studies of multifaceted
interventions met the inclusion criteria.
124 imulate global supply chains, food demand
is met from an international pool (where the origin can be
125 ide-supported materials, this requirement
is met only at the perimeters of metal nanoparticles.
126 When the rule
is met, we added the mandatory use of fortified topical ant
127 d WB when compared with prolactinomas but
it met the statistical significance criteria (p <= 0.0028)
128 osocimab 0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/
kg met criteria for noninferiority compared with enoxaparin
129 A total of 2005
men met inclusion criteria and completed the baseline and at
130 cm as the cutoff, 72% of women and 9% of
men met criteria.
131 hocardiogram, and together with JUP
mutation met definite ARVC diagnosis.
132 s on the quality of the numbers that are
not met by many methods.
133 en the assumptions of WQS regression are
not met.
134 gurations emerge if these conditions are
not met: 1) collapsed, 2) monopolar, and 3) multipolar spind
135 tions underlying trait-based studies are
not met?
136 ase in the demand for testing, which, if
not met with adequate supply, may render the app counterprod
137 ults show that if the Paris Agreement is
not met, Antarctica's long-term sea-level contribution will
138 However, this target was
not met at the 50-copies/mL threshold or in intention-to-tre
139 prespecified threshold for activity was
not met in the trial, we believe that the preliminary antitu
140 Although the primary endpoint was
not met, the results of this trial suggest a beneficial impa
141 rimary study end point, 3-year BPFS, was
not met.
142 l tolerated but the primary endpoint was
not met.
143 treatment, however trial endpoints were
not met after 48 weeks.
144 f day 28 clinical response criteria were
not met, further oral antibiotics were prescribed until clin
145 -0.86; one-sided p=0.0012 [primary
objective met]).
146 The lack of transferability is
often met with a largely empirical approach to optimizing cata
147 utional study, 162 patients (7-18 years
old)
met our inclusion criteria with a mean age of 13.4 years
148 from scientific societies and
organizations met to discuss possible solutions for funding and retain
149 the preoperative 1.8-mg/kg dose of
osocimab met criteria for superiority compared with enoxaparin fo
150 Of 128 enrolled, 100
participants met inclusion criteria (mean age, 48.6 years; 41 men).
151 In total, 223 of 266
participants met neuropathological diagnostic criteria for CTE.
152 Overall, 847
participants met the study inclusion criteria.
153 hundred five eyes of 986 AREDS2
participants met the inclusion criteria; of these, 977 participants (
154 Thirty-three percent of LLD
participants met ADNI criteria for mild cognitive impairment.
155 over 6 months, 17 healthy male
participants met inclusion criteria and completed donations and psych
156 535 patients were reviewed, and 12
patients met inclusion criteria.
157 A total of 17
patients met the inclusion criteria.
158 240 eyes in 203
patients met criteria for analysis (38 eyes were lost to follow u
159 ns were reviewed and a total of 208
patients met the inclusion criteria.
160 2161
patients met eligibility criteria with 876 (41%) transitioned to
161 Most of these 25
patients met clinical criteria for an inflammatory syndrome (rela
162 In total, 407
patients met final inclusion criteria (332 adults, 75 children).
163 Of these, 433
patients met criteria for hemostatic efficacy evaluation.
164 Overall, 572
patients met eligibility criteria with 2855 patient-years of foll
165 A total of 37 and 98
patients met criteria in the pre- and post-IVAT periods, respecti
166 One hundred eight
patients met inclusion criteria; 47% (n = 51) received an extende
167 Forty-five
patients met inclusion criteria.
168 Nine
patients met inclusion criteria.
169 Next, we determined how many of the
patients met the same criteria at other points in time.
170 Thirteen
patients met both inclusion and exclusion criteria, and their tis
171 Four hundred three
patients met study criteria: 313 (78%) without adjuvant therapy a
172 l to 6 hours and determined whether
patients met complete pediatric acute respiratory distress syndro
173 Eighty-four eyes (55
patients)
met the inclusion criteria.
174 Osocimab given
postoperatively met criteria for noninferiority compared with enoxaparin
175 All
programs met queueing time and distance indicators, did not meet
176 ur studies (reported across 76
publications)
met the selection criteria.
177 ed 10,596 unique articles, of which 403
RCTs met inclusion criteria.
178 enging applications which can not be
readily met by conventional FT-IR spectroscopy.
179 A total of 3334
recipients met inclusion criteria including 155 (5%) and 3179 (95%)
180 ponded, and 87.1% (825 of 946) of
responders met eligibility criteria.
181 of the 34 articles selected for full
review met all inclusion criteria for this assessment.
182 Twenty-two Cochrane
reviews met the inclusion criteria.
183 rimary studies and three systematic
reviews)
met the inclusion criteria.
184 Lung-MAP (
S1400)
met its goal to quickly address biomarker-driven therapy
185 Of 220 patients screened, 199 with
SAB met study criteria and were included in the investigatio
186 In total, 1,710
samples met inclusion criteria.
187 se on Nov 7-8, 2018; of 1409 articles,
seven met the inclusion criteria.
188 rculosis, the sensitivity at 90%
specificity met or approached the benchmarks set out in World Health
189 (3.7%), who were assigned the Orsiro
stent,
met the primary end point (absolute risk difference 1.29
190 was stopped early and no treatment
strategy met prespecified criteria for statistical superiority, p
191 esearch articles identified, only 12
studies met the inclusion criteria, with 10 studies being eventu
192 e initial pool of 3,204 records, 152
studies met our inclusion criteria (11,815/11,528, 233/219, and
193 Of 7,300 unique citations, 22
studies met the inclusion criteria and were of sufficient qualit
194 A total of 35
studies met inclusion criteria and form the evidence base, inclu
195 rticles were assessed in full and 37
studies met the inclusion criteria.
196 Of 7408 identified records, 44
studies met inclusion.
197 Both
studies met both the coprimary end points.
198 Sixty-eight
studies met the inclusion criteria.
199 nd seven clinical (n = 164 patients)
studies met eligibility.
200 Twelve
studies met inclusion criteria.
201 A total of twelve
studies met the inclusion criteria and were included in the revi
202 Thirty-two
studies met the inclusion criteria, 27 in the lung, four in the
203 ient series, and 11 pharmacokinetic
studies)
met inclusion criteria regarding the effect of extracorp
204 tified, 36 articles, relating to 30
studies,
met the eligibility criteria.
205 No
study met criteria for level I evidence.
206 The
study met its primary endpoint, showing a significant differen
207 The
study met its primary endpoint: the fixed-dose combination of
208 The
study met the primary endpoint, as 12 of 20 (OS3, 0.60; 90% co
209 This
study met criteria to move forward to a future randomised tria
210 Our POC test
suitably met the urgent needs of ports of entry, airports, and en
211 There were 9,087 patients (54.7%)
that met systemic inflammatory response syndrome-first a medi
212 ynthesized data from full-text articles
that met inclusion criteria.
213 the top 12 NDD genes with damaging DNVs
that met statistical significance after Bonferroni correction
214 e 3 or higher adverse events and events
that met liver-related stopping criteria occurred in 11% and
215 of participants had phenotypic features
that met the diagnostic criteria for more than one syndrome.
216 D); in eyes with toric IOL implantation
that met certain inclusion criteria, 80%, 84%, and 69% of eye
217 e interval [CI], -2.8 to 2.1), a result
that met the criterion for noninferiority for the primary end
218 points; 95% CI, -3.7 to 4.5), a result
that met the criterion for noninferiority for this end point
219 We identified 89 studies
that met our inclusion criteria for the systematic review, an
220 We identified 41 studies
that met our inclusion criteria involving 112,034 patients in
221 We included 18 studies
that met our strict eligibility criteria.
222 A total of 100 volunteers
that met established criteria were enrolled in the study: 36
223 up contrasts from all individual voxels
that met spectral quality, were analyzed in common brain spac
224 omized controlled trials of systemic
therapy met eligibility criteria.
225 ka virus disease cases were included if
they met the national surveillance case definition, had illne
226 coinfected individuals were included if
they met: 1) SVR with DAA-based combination; 2) Liver stiffne
227 re, opportune, or delayed based on when
they met readiness-to-wean criteria.
228 IQR 6.5-9.3), overall response and C(
trough)
met the predefined non-inferiority criteria.
229 one shared paper between New Zealand and
UK met the inclusion criteria.
230 the 3948 articles identified, 24
ultimately met the inclusion criteria.
231 Veritor met FDA emergency use authorization (EUA) acceptance cri
232 fter randomization, the primary endpoint
was met in 6 (12%) DJBL patients and 3 (10%) controls (P = 0
233 The study endpoint
was met when ILA were extensive or when ILD was diagnosed cl
234 The primary endpoint
was met: ACR20 at week 24 was achieved by significantly grea
235 The primary objective
was met in six of the nine patients at 12 months follow-up,
236 The enrollment goal of 125 patients
was met.
237 han half of the need for family planning
was met in Middle and Western Africa.
238 The primary end point
was met by 59 (35%) with combination therapy and 68 (39%) wi
239 ed elagolix alone, the primary end point
was met in 84.1% of 104 women in UF-1 and in 77% of 95 women
240 The primary end point
was met, with an sCR rate of 60% after 8 cycles.
241 The primary end point
was met, with the ORR reaching 60.9% (95% CI, 45.4% to 74.9%
242 were prescribed until clinical response
was met.
243 ne whether the required information size
was met for each outcome.
244 The required information size
was met for our primary outcome and trial sequential analysi
245 Primary success
was met by 73%.
246 ia for posttransplant metabolic syndrome
was met in 34.6% of EW versus 17.6% of non-EW cohorts (P = 0
247 Therefore,
we met the IUCN's challenge by testing a sampling technique
248 criteria were met and Questionable if 2
were met.
249 Swansea criteria to diagnose AFLP
were met by all patients with PAALD and also by virtually all
250 s considered Definite if all 3 criteria
were met and Questionable if 2 were met.
251 If rejection criteria
were met, a committee mock-refused PCR unless the patient was
252 t week 24, if rescue treatment criteria
were met, IAI patients received laser therapy, and laser ther
253 Since the primary endpoints
were met at the first interim analysis, updated data are repo
254 rimary and secondary efficacy endpoints
were met, with posterior probability of superiority more than
255 Both primary endpoints
were met.
256 All prespecified endpoints
were met.
257 Both primary endpoints
were met: ASAS40 at week 16 (ixekizumab Q4W: 34 [35%] of 96,
258 Criteria for the primary end point
were met in 68.5% of 206 women in UF-1 and in 76.5% of 189 wo
259 ere reviewed by the Delphi panel, 8 of
which met criteria for inclusion and were combined into a fina
260 ially appropriate studies, 35 (88%) of
which met the eligibility criteria and were included in the fi
261 Indiana University between 1990 and 2016
who met inclusion criteria.
262 went esophagectomy between 1991 and 2017
who met inclusion criteria and were contactable, responded t
263 SO palsy; 54 congenital and 11 acquired,
who met the study criteria and were classified into 3 groups
264 ldren who were 2 to 59 months of age and
who met WHO criteria for nonsevere pneumonia with tachypnea
265 Results: Among 1,117 patients with ARDS
who met inclusion criteria, the median Crs was 30 (interquar
266 Among 1,889,032 Medicare beneficiaries
who met inclusion criteria 560,744 (n = 29.7%) individuals h
267 his case series of hospitalized children
who met criteria for PIMS-TS, there was a wide spectrum of p
268 5.7-14]; 20 girls [34%]) were identified
who met the criteria for PIMS-TS.
269 ly one-third of heterosexual individuals
who met criteria for a past-year alcohol use disorder did.
270 5%) and gay or lesbian (51%) individuals
who met criteria for a past-year alcohol use disorder had a
271 here were 418,965 patients with migraine
who met the study criteria and were included in the analysis
272 hine learning model to identify patients
who met a composite endpoint of hospital-based intervention
273 g-based disease progression for patients
who met certain criteria.
274 mean of 2.2 days compared with patients
who met criteria but did not have the alert fire (8.0 vs 5.8
275 13 (10%) of 134 patients
who met criteria for ICU admission were admitted to ICU; the
276 There were 22 958 patients
who met inclusion criteria.
277 l mortality were 39% greater in patients
who met systemic inflammatory response syndrome-first compar
278 arning model and GBS identified patients
who met the composite endpoint with 100% sensitivity, the sp
279 chine learning model identified patients
who met the composite endpoint with an AUC of 0.90, the GBS
280 chine learning model identified patients
who met the composite endpoint with an AUC of 0.91 in the in
281 ical scoring systems identified patients
who met the composite endpoint with AUC values of 0.88 for t
282 A total of 78 patients
who met the criteria of difficult cannulation in the Nationa
283 Twenty-nine patients
who met the eligibility criteria (responders, n = 14, and no
284 Response was assessed in all patients
who met the eligibility criteria and who received at least 8
285 Of 37,050 patients
who met the eligibility criteria, 529 patients (1.4%) develo
286 We included 18 128 patients
who met the inclusion criteria.
287 e for low-risk patients and for patients
who met the Kidney Disease: Improving Global Outcomes urine
288 re significantly worse than for patients
who met the Kidney Disease: Improving Global Outcomes urine
289 Of the 1,595 PLHIV
who met eligibility criteria, the majority (61%) were inpati
290 Subjects
who met DSM-5 criteria for alcohol use disorder (AUD; n = 17
291 ied a substantial proportion of subjects
who met the criteria for noncompliance within the trials ana
292 term outcomes and hospitals and surgeons
who met minimum volume thresholds for lung cancer resection
293 ients with fever or respiratory symptoms
who met criteria for antiviral treatment, per 2013 CDC guide
294 Patients in the health system
who met inclusion criteria were >=18 years old, had a body m
295 milar differences were found among those
who met criteria for a past-year tobacco use disorder.
296 ed patients with logopenic PPA and those
who met criteria for PPA but not a specific subtype.
297 ponse syndrome-first compared with those
who met Sequential Organ Failure Assessment-first (odds rati
298 Among those
who met WHO pneumonia criteria, 8.6% (189/2199) experienced
299 The data of the women
who met the inclusion criteria were linked to the data of th
300 bian SAO system, finding that it has not
yet met, but is working towards achieving, the targets set b